{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:51:14Z","timestamp":1753890674554,"version":"3.41.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Type 2 diabetes leads to an increase in the prevalence of lipid abnormalities, which increases the risk of cardiovascular disease. Therefore, current guidelines generally recommend the use of moderate or high-intensity statins in patients with type 2 diabetes. There are still few studies on the overall risk benefit balance of statins for acute myocardial infarction (AMI) patients with diabetes. Compared with other types of lipid-lowering drugs, the advantage of statins for the prognosis of patients with AMI has not yet been determined. We investigated the effects of statins and non-statins on intensive care unit (ICU) and inpatient mortality in patients with AMI and diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study retrospectively collected all patients with AMI and diabetes in the Medical Information Mart Intensive Care-IV database. We assessed ICU and in-hospital mortality rates during hospitalization in both groups. The clinical end point was in-hospital mortality and ICU mortality. Kaplan-Meier and Cox proportional-hazards regression models were applied to analyze the correlation between the two groups and the outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data on 1,315 patients with AMI and diabetes were collected, among which 1,211 used statins during hospitalization. The overall in-hospital mortality of patients with AMI and diabetes was 17.2%, and the total ICU mortality was 12.6%. The in-hospital mortality was lower for the statin group than for the non-statin group (13.9% and 55.8%, respectively). Kaplan-Meier survival curves demonstrated that survival probability was higher in the statin group than in the non-statin group. In the cohort without hyperlipidemia, the statin group had lower risks of ICU death (HR = 0.12, 95% CI = 0.04\u20130.40) and in-hospital death (HR = 0.36, 95% CI = 0.16\u20130.84) compared with the non-statin group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Statins can significantly reduce ICU and in-hospital mortality rates in patients with AMI and diabetes. Even in the population without hyperlipidemia, statins can still reduce the mortality in patients with AMI and diabetes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.976656","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T05:56:20Z","timestamp":1659938180000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Association between statin use and the prognosis of patients with acute myocardial infarction complicated with diabetes"],"prefix":"10.3389","volume":"9","author":[{"given":"Xuehao","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaojin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongsheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global estimates of the prevalence of diabetes for 2010 and 2030","volume":"87","author":"Shaw","year":"2010","journal-title":"Diabetes Res Clin Pract."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.amjmed.2007.01.002","article-title":"Multiple risk factors for cardiovascular disease and diabetes mellitus","volume":"120","author":"Smith","year":"2007","journal-title":"Am J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1046\/j.1365-2796.2002.00959.x","article-title":"Cardiovascular prevention before admission reduces mortality following acute myocardial infarction in patients with diabetes","volume":"251","author":"Londahl","year":"2002","journal-title":"J Intern Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","article-title":"Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)","volume":"316","author":"Turner","year":"1998","journal-title":"BMJ."},{"key":"B5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2165\/1158822-S0-000000000-00000","article-title":"Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering","volume":"10","author":"Pedersen","year":"2010","journal-title":"Am J Cardiovasc Drugs."},{"key":"B6","doi-asserted-by":"publisher","first-page":"CD004816","DOI":"10.1002\/14651858.CD004816.pub5","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"2013","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc20-S010","article-title":"10. Cardiovascular disease and risk management:","volume":"43","year":"2020","journal-title":"Standards of Medical Care in Diabetes-2020. Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s12872-021-02198-w","article-title":"Comparative effect of statin intensity between prediabetes and type 2 diabetes mellitus after implanting newer-generation drug-eluting stents in Korean acute myocardial infarction patients: a retrospective observational study","volume":"21","author":"Kim","year":"2021","journal-title":"BMC Cardiovasc Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e24733","DOI":"10.1097\/MD.0000000000024733","article-title":"Effect of statin treatment in patients with acute myocardial infarction with prediabetes and type 2 diabetes mellitus: a retrospective observational registry study","volume":"100","author":"Kim","year":"2021","journal-title":"Medicine."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2840-9-1","article-title":"Long-term prognosis of diabetic patients with acute myocardial infarction in the era of acute revascularization","volume":"9","author":"Takara","year":"2010","journal-title":"Cardiovasc Diabetol."},{"volume-title":"MIMIC-IV (version 1.0)","year":"2021","author":"Johnson","key":"B13"},{"key":"B14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40779-021-00338-z","article-title":"Data mining in clinical big data: the frequently used databases, steps, and methodological models","volume":"8","author":"Wu","year":"2021","journal-title":"Mil Med Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.15829\/1560-4071-2020-3826","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/ NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s11883-014-0472-7","article-title":"Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10?","volume":"17","author":"Chan","year":"2015","journal-title":"Curr Atheroscler Rep."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-12-S1-S3","article-title":"Statin diabetogenicity: guidance for clinicians","volume":"12","author":"Ray","year":"2013","journal-title":"Cardiovasc Diabetol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12933-017-0587-6","article-title":"Effects of background statin therapy on glycemic response and cardiovascular events following initiation of insulin therapy in type 2 diabetes: a large UK cohort study","volume":"16","author":"Anyanwagu","year":"2017","journal-title":"Cardiovasc Diabetol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.03.030","article-title":"Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review","author":"Abourbih","year":"2009","journal-title":"Am J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"g4379","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients","volume":"349","author":"Keene","year":"2014","journal-title":"BMJ."},{"key":"B23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijcard.2015.04.228","article-title":"Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: a meta-analysis of randomized controlled trials","volume":"191","author":"Ip","year":"2015","journal-title":"Int J Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijcard.2016.09.082","article-title":"Clinical outcome of statin plus ezetimibe versus high-intensity statin therapy in patients with acute myocardial infarction propensity-score matching analysis","volume":"225","author":"Ji","year":"2016","journal-title":"Int J Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1177\/2047487318766612","article-title":"A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes","volume":"25","author":"Khan","year":"2018","journal-title":"Eur J Prev Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Group","year":"2014","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.tcm.2019.01.001","article-title":"Effect of statins on atherosclerotic plaque","volume":"29","author":"Almeida","year":"2019","journal-title":"Trends Cardiovasc Med."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.976656\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T05:56:23Z","timestamp":1659938183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.976656\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":27,"alternative-id":["10.3389\/fcvm.2022.976656"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.976656","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2022,8,8]]},"article-number":"976656"}}